Note: This feature on the best-selling pharmaceuticals of 2023 will be updated regularly as new data becomes available. Stay tuned for our ongoing coverage of the pharma sector’s sales dynamics.
[Scanrail/Adobe Stock]
In 2023, as the grip of the COVID-19 pandemic began to loosen, the pharma sector returned to relying on immunology and oncology as sales drivers. So far this year, the two segments are on track to be the strongest in the pharma landscape. In the first half of 2023, the immunology and oncology domains drove sales of $31.110 billion and $37.982 billion, respectively, based on a review of financial data from 13 Big Pharma companies. Conversely, the infectious disease segment accumulated sales of approximately $28.587 billion.Contrasting the boom of prior years, 2023 has seen a pronounced dip in the appetite for SARS-CoV-2 vaccines. For instance, the Pfizer-BioNTech vaccine generated roug…